NOROMBY HP SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

ENOXAPARIN SODIUM

Доступна з:

JUNO PHARMACEUTICALS CORP.

Код атс:

B01AB05

ІПН (Міжнародна Ім'я):

ENOXAPARIN

Дозування:

120MG

Фармацевтична форма:

SOLUTION

Склад:

ENOXAPARIN SODIUM 120MG

Адміністрація маршрут:

INTRAVENOUS

Одиниць в упаковці:

15G/50G

Тип рецепту:

Prescription

Терапевтична области:

HEPARINS

Огляд продуктів:

Active ingredient group (AIG) number: 0131860002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2020-10-14

Характеристики продукта

_ _
_NOROMBY _
_Page 1 of 78_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NOROMBY
TM
Enoxaparin sodium
Solution for injection, 100 mg/mL
BP
20 mg/0.2 mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
(Subcutaneous or Intravenous Use Only)
Pr
NOROMBY
TM HP
Enoxaparin sodium
Solution for injection, 150 mg/mL
BP
120 mg/0.8 mL
150 mg/mL
(Subcutaneous or Intravenous Use Only)
ATC Code: B01AB05
Anticoagulant/Antithrombotic Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Initial Approval:
October 14, 2020
Date of Revision:
February 12, 2021
Submission Control No: 233058
_ _
_NOROMBY _
_Page 2 of 78_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................4
1
INDICATIONS
..............................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics
............................................................................................................4
2
CONTRAINDICATIONS................................................................................................4
3
DOSAGE AND
ADMINISTRATION...............................................................................5
3.1
Dosing
Considerations.........................................................................................5
3.2
Recommended Dose and Dosage Adjustment
.....................................................5
3.3
Administration
.....................................................................................................8
3.4
Missed Dose
.....................................................................................................10
4
OVERDOSAGE
..........................................................................................................10
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND
PACKAGING................